Evicenter
MarkdownMedical informationP&T meetings
VK2735

Chronic weight management

Last updated
184 sources

Clinical evidence

VK2735-102 part 2 oral and subcutaneous maintenance

27 evidence topics · 7 sources

Objective
Location and study date
Study dates and United States sites in the ClinicalTrials.gov record (both study parts)
FieldRegistry value
Recruitment status“Recruiting”
Primary completion (estimated)“2027-05”
Study completion (estimated)“2027-07”
Site 1 city“Lake Forest”
Site 2 city“Miami”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets

No evidence found.

Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations
Summary: study limitations

Part 2 of the VK2735-102 study began in October 2026, and no results have been reported; the company expects results in 2027. It is a phase 1 trial in approximately 195 otherwise healthy adults with a body mass index of at least 30 kg/m2, with a 12-week maintenance period after 21 weeks of weekly subcutaneous induction, a primary endpoint of treatment-emergent adverse events, and body weight change as an exploratory endpoint. The documents disagree on the regimens. The initiation release of 6 October 2026 listed “weekly oral doses”, and a correction note issued on 14 October 2026 removed them; the ClinicalTrials.gov record still lists a group receiving VK2735 “orally weekly” and a group receiving placebo “orally once weekly”. The registry describes 6 Part B arms receiving “one of four VK2735 dose regimens or matching placebo regimen”, while the chief executive officer described five oral arms and six subcutaneous arms. The oral doses have not been disclosed; the September 2026 call named 17.5, 27.5, and 55 mg, and the October 2026 call gave a range of about 17 to 55 mg. The registry estimate of 270 participants for both parts is smaller than the sum of the 180 participants randomized in Part 1 and the approximately 195 planned for Part 2.